News

The FlowSkin® platform : a unique ex vivo perfused human skin model to test pharmacokinetic and systemic administration in human skin When human tissue culture meets microfluidic technology, it leads to the first perfused human skin model ; an amazing platform to overcome the challenges of drug development and replace animal testing. Almost 10 years ago now, Genoskin developed theRead more

Genoskin & LEO Pharma publish data on inflammation model InflammaSkin® in Experimental Dermatology Genoskin’s amazing team of experts is always developing new and improved ex vivo human skin assays. This time, we partnered with LEO Pharma to develop a brand new inflammation model: InflammaSkin®. Genoskin is proud to announce that its unique skin assay is now fully described in ExperimentalRead more

Genoskin, a biotechnology company developing ready-to-use human skin biopsies for ex vivo clinical testing, announces today the launch of its newest offering, NativeSkin^® access, a ready-to-use standardized skin model.

Genoskin featured in a Business Insider article The press is talking about Genoskin! Amid COVID-19 breakout, Genoskin got attention from Business Insider 's reporter Mia Jankowicz.  We recently communicated on our continued efforts during the pandemic and our preferred access program for research on COVID-19. Genoskin's projects and technology caught the eye of Mia Jankowicz. Mia, a journalist specializing inRead more

Genoskin COVID-19 research preferred access program On Friday, March 13th 2020, Genoskin launched a preferred access program for all research teams actively developing therapeutic and vaccine technologies for the COVID-19 pandemic. The World Health Organization (WHO) officially declared on March 11th, the outbreak of COVID-19 a pandemic. The disease caused by SARS-CoV-2 has spread globally. Over 130,000 individuals are affected so

Read more

Genoskin reinforces R&D capabilities Genoskin Research & Development offers new services to portfolio available to partners with the addition of new equipment. Genoskin's R&D recently added a Meso Scale QuickPlex SQ120 for high-performance electroluminescence immunoassays. This new instrument will enable our teams to detect the presence of biomarkers down to femtoscale concentrations. Genoskin also added a best-in-class solar simulator (Solar Light) capable ofRead more